Amgen Inc (AMGN)

[Scorpion King]

Adva-27a is a GEM-difluourinated C-glycoside derivative of Podophyllotoxin that Sunshine is developing for various forms of drug-resistance cancers, most impressively topoisomerase 2-positive breast cancer patients. Competition in the oncology community is a short list, primarily etoposide, which is also a derivative of Podophyllotoxin. However, etoposide is ineffective against multi-drug resistant cancer lines, giving Adva-27a, as a completely new chemical entity, a distinct advantage and substantial area for market penetration. As such, it also likely makes it very attractive for partnering or acquisition opportunities to big pharma should clinical trials support the laboratory research.